Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mersana Therapeutics, a platform-based cancer therapeutics company, has named Nicholas Bacopoulos as the president and CEO of the company.
Subscribe to our email newsletter
Most recently, Bacopoulos worked as president and CEO of Aton Pharma.
Prior to Aton Pharma, Bacopoulos served as the president and head of R&D at OSI Pharmaceuticals, where he worked on the development of Tarceva and the R&D integration of the British Biotechnology and Gilead Oncology acquisitions.
Mersana chairman of the board Boyd Clarke said that they are pleased that Nick has decided to join Mersana as president and CEO.
“His extensive operational leadership and drug development experience will be invaluable as they continue to exploit the broad therapeutic applications of Fleximer-based platform,” Clarke said.